Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab
Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab
Recruiting · NCT06816927 · Registry updated 2026-09-17Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab | Newly Diagnosed Glioblastoma | Recruiting | Phase 2 | 2026-09-17 | NCT06816927 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Duke University | 446 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Duke University | Durham | United States | 2 |
| Memorial Sloan Kettering Cancer Center | New York | United States | 1000 |
| Peter MacCallum Cancer Centre | Parkville | Australia | 2 |
| University of Texas MD Anderson Cancer Center | Houston | United States | 192 |